Cargando…

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Gene mutations independent of BCR::ABL1 have been identified in newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in epigenetic modifier genes were most common. These findings prompted the systematic analysis of prevalence, dynamics, and prognostic sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schönfeld, Lioba, Rinke, Jenny, Hinze, Anna, Nagel, Saskia N., Schäfer, Vivien, Schenk, Thomas, Fabisch, Christian, Brümmendorf, Tim H., Burchert, Andreas, le Coutre, Philipp, Krause, Stefan W., Saussele, Susanne, Safizadeh, Fatemeh, Pfirrmann, Markus, Hochhaus, Andreas, Ernst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417980/ https://www.ncbi.nlm.nih.gov/pubmed/35902731 http://dx.doi.org/10.1038/s41375-022-01648-4

Ejemplares similares

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
por: Le Coutre, Philipp, et al.
Publicado: (2023)

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
por: Giles, Francis J., et al.
Publicado: (2017)

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation
por: Hinze, Anna, et al.
Publicado: (2020)

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
por: Radich, Jerald P., et al.
Publicado: (2021)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
por: Ross, David M., et al.
Publicado: (2018)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
por: Hochhaus, A, et al.
Publicado: (2017)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
por: Hochhaus, A, et al.
Publicado: (2016)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Survival with chronic myeloid leukaemia after failing milestones
por: Lauseker, Michael, et al.
Publicado: (2023)

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
por: Hochhaus, Andreas, et al.
Publicado: (2017)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
por: Ayoub, Maya C., et al.
Publicado: (2023)

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish
por: Gjini, Evisa, et al.
Publicado: (2019)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
por: Hochhaus, A, et al.
Publicado: (2016)

EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders
por: Midic, Danica, et al.
Publicado: (2020)

Functional and cancer genomics of ASXL family members
por: Katoh, M
Publicado: (2013)

ASXL1 plays an important role in erythropoiesis
por: Shi, Hui, et al.
Publicado: (2016)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
por: Georgi, Julia-Annabell, et al.
Publicado: (2023)

P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

ASXL1 mutations in Chinese patients with essential thrombocythemia
por: Nie, Yan-Bo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cpf6j3ncmlvrnunnp5nssddame